Aerovate Therapeutics Analyst Ratings
Aerovate Therapeutics Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 12/06/2022 | 73.63% | BTIG | → $27 | Upgrades | Neutral → Buy |
| 08/16/2022 | — | BTIG | Downgrades | Buy → Neutral | |
| 02/11/2022 | 54.34% | BTIG | → $24 | Initiates Coverage On | → Buy |
| 07/26/2021 | 92.93% | Evercore ISI Group | → $30 | Initiates Coverage On | → Outperform |
| 07/26/2021 | — | Cowen & Co. | Initiates Coverage On | → Outperform | |
| 07/26/2021 | 47.91% | Wedbush | → $23 | Initiates Coverage On | → Outperform |
| 07/26/2021 | 35.05% | Jefferies | → $21 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 12/06/2022 | 73.63% | BTIG | → $27 | 升級 | 中性→購買 |
| 08/16/2022 | — | BTIG | 評級下調 | 購買→中性 | |
| 02/11/2022 | 54.34% | BTIG | → $24 | 開始承保 | →購買 |
| 07/26/2021 | 92.93% | Evercore ISI集團 | → $30 | 開始承保 | →跑贏大盤 |
| 07/26/2021 | — | 考恩公司 | 開始承保 | →跑贏大盤 | |
| 07/26/2021 | 47.91% | 韋德布什 | → $23 | 開始承保 | →跑贏大盤 |
| 07/26/2021 | 35.05% | 傑富瑞 | → $21 | 開始承保 | →購買 |
What is the target price for Aerovate Therapeutics (AVTE)?
Aerovate Treeutics(AVTE)的目標價格是多少？
The latest price target for Aerovate Therapeutics (NASDAQ: AVTE) was reported by BTIG on December 6, 2022. The analyst firm set a price target for $27.00 expecting AVTE to rise to within 12 months (a possible 73.63% upside). 3 analyst firms have reported ratings in the last year.
BTIG於2022年12月6日報道了Aerovate治療公司(納斯達克：AVTE)的最新目標價。這家分析公司將目標價定為27美元，預計中興通訊將在12個月內上漲至73.63%(可能上漲73.63%)。3家分析公司在過去一年公佈了評級。
What is the most recent analyst rating for Aerovate Therapeutics (AVTE)?
Aerovate Treeutics(AVTE)的最新分析師評級是什麼？
The latest analyst rating for Aerovate Therapeutics (NASDAQ: AVTE) was provided by BTIG, and Aerovate Therapeutics upgraded their buy rating.
對Aerovate Treateutics(納斯達克股票代碼：AVTE)的最新分析師評級由北歐國際集團提供，Aerovate治療公司上調了買入評級。
When is the next analyst rating going to be posted or updated for Aerovate Therapeutics (AVTE)?
Aerovate治療公司(AVTE)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Aerovate Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Aerovate Therapeutics was filed on December 6, 2022 so you should expect the next rating to be made available sometime around December 6, 2023.
分析師在進行了廣泛的研究後得出股票評級，其中包括查閲公共財務報表，與Aerovate治療公司的高管和客户交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。Aerovate治療公司的上一次評級是在2022年12月6日提交的，所以你應該預計下一次評級將在2023年12月6日左右提供。
Is the Analyst Rating Aerovate Therapeutics (AVTE) correct?
分析師對Aerovate Treeutics(AVTE)的評級正確嗎？
While ratings are subjective and will change, the latest Aerovate Therapeutics (AVTE) rating was a upgraded with a price target of $0.00 to $27.00. The current price Aerovate Therapeutics (AVTE) is trading at is $15.55, which is within the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的Aerovate治療(AVTE)評級被上調，目標價從0.00美元到27.00美元。Aerovate治療公司(AVTE)目前的交易價格為15.55美元，在分析師的預測範圍內。